Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIA: Venetoclax Combinations in First-line Fit CLL
NCT02950051Phase 3Completed
- Sponsor
- German CLL Study Group
- Start
- Dec 2016
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL) (4 arms), sponsored by German CLL Study Group. Primary endpoints: Minimal Residual Disease Negativity Rate in Peripheral Blood at Month 15 and Progression-Free Survival at Month 73. Started Dec 2016; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02950051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950051.